Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a bet. Exact’s test could compete with ...

The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting ...

The campaign remains ongoing as part of Exact’s health equity efforts, with its respective English- and Spanish-language websites still offering a range of information about colon cancer screening.

iOS and iPadOS also let you remove location data from the Preview app. Open the image, then tap on the ellipsis (...) icon at ...

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease.

Shares of Exact Sciences (NASDAQ:EXAS) gained on Wednesday after the maker of the Cologuard stool-based cancer test announced plans to release data from a blood-based cancer test on Sept.

The investigation into what caused the Davis Fire includes looking at videos and running license plate numbers of people ...

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...

MADISON, Wis., August 28, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the ...

A former FBI assistant director said “there are only three possible answers” to how Ryan Routh knew the exact details of ...